Featured article

Bausch + Lomb and Nicox’s Glaucoma Candidate VESNEO® (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies


“VESNEO was discovered in our Research Laboratories in Milan and we are encouraged by these promising results from Bausch + Lomb’s pivotal Phase 3 studies,” said Michele Garufi, chairman and CEO of Nicox.

[Read more]